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INTRODUCTION
Chronic alcohol consumption is the most prevalent etio-
logic factor of hepatic fibrogenesis and cirrhosis (1). Ethanol
is metabolized primarily by the alcohol dehydrogenase and
the cytochrome P450 systems (2). Acetaldehyde generated
by these oxidative pathways is accumulated due to slow kinetics
of its oxidizing enzyme aldehyde dehydrogenase (3). Ethanol
and acetaldehyde affect liver with directly generating reactive
oxygen species (ROS) and indirectly producing transforming
growth factor beta (TGF-β ) (3). Patients with alcohol induced
liver cirrhosis had significantly more leucine homozygous
genotype polymorphism of TGF-β 1 at codon 10 in Korean
(4). TGF-βis a growth factor whose function is promotion
of cell differentiation, fibrosis, angiogenesis, apoptosis, and
suppression of cell proliferation (5, 6). TGF-βalso mediates
alcoholic liver diseases by hepatic apoptosis, hepatic fibroge-
nesis and suppression of hepatocyte proliferation (7, 8). Among
three of its subtypes TGF-β 1 is the most abundant and uni-
versally expressed isoform (9). In animal study, ethanol meta-
bolite acetaldehyde increase autocrine TGF-β 1 expression in
hepatic stellate cells (10). This TGF-β 1 increases the produc-
tion of extracellular matrix proteins and decreases the matrix-
degrading proteolytic enzymes (11). In addition to these liver
fibrosis inductions, TGF-β damages alcoholic liver with trig-
gering hepatocyte apoptosis, and inhibiting hepatocyte pro-
liferation (7, 8). In nervous system, TGF-β 1 controls neuronal
migration and neurite outgrowth by regulating cell adhesion
proteins (12, 13).
There were many reports of increased TGF-βin ethanol
treated rats in previous animal studies (14, 15). But human
alcoholism study comparable has not been. In order to veri-
fy the relation between alcohol dependence and TGF-β , we
measured TGF-βin patients with alcohol dependence, and
compared it with control subjects. 
MATERIALS AND METHODS
Human subjects
We assessed the peripheral TGF-β 1 levels in the plasma
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Increased Transforming Growth Factor-beta1 in Alcohol Dependence
Ethanol and its metabolite acetaldehyde increase transforming growth factor beta1
(TGF-β 1) expression in animal studies. TGF-β 1 is related with the hepatic stellate
cell (the key element of hepatic fibrogenesis) and the radial glia (the key element
of neuronal migration). Blood samples were collected from 41 patients with alcohol
dependence, TGF-β 1 levels measured by ELISA were compared with 41 normal
subjects. Plasma TGF-β 1 levels in the patients with alcohol dependence (1,653.11
±532.45 pg/mL) were significantly higher than those of healthy subjects (669.87
±366.53 pg/mL) (P=0.000). Patients with or without liver pathology showed no dif-
ference in TGF-β 1 (P=0.36). Increased TGF-β 1 may mediate deleterious effect of
alcohol such as hepatic fibrosis and suppressed neuronal developments in alcohol
dependence patients.
Key Words : Alcohols; Transforming Growth Factor beta1
Received : 12 June 2008
Accepted : 1 October 2008of alcohol dependence patients and healthy controls. Forty-
one male patients who met the Diagnostic and Statistical
Manual of Mental Disorder IV (DSM-IV) criteria for alco-
hol dependence were interviewed and sampled. They were
all admitted to psychiatric closed ward in Hangang Sacred
Heart Hospital. Two or more psychiatrists at the hospital
carried out the diagnosis in a consensus procedure using all
available clinical material, including a semi-structured inter-
view based on DSM-IV. Patients were excluded from the study
if they had a history of comorbid psychiatric illness, addic-
tion to drugs other than alcohol or nicotine, physical disor-
ders other than alcohol-related medical illness, and any neu-
rological disease. Medical consultation were done to find any
liver pathology which could affect TGF-β 1 level. The com-
parison subjects comprised 41 unrelated healthy males who
were employees of Hangang Sacred Heart Hospital. Most of
the participating employees were nondrinkers; only some were
occasional light drinkers (persons who drink occasionally but
have lower score than cut-off value of AUDIT-K), as revealed
by a drinking-habit questionnaire. The study was approved
by the hospital ethics committee (Han-Gang Sacred Heart
Hospital).
TGF-β 1 plasma levels
Ten mL of venous blood was collected within 24 hr after
admission and stored at -70℃. Plasma TGF-β 1 level was
determined by capture ELISA using monoclonal anti-human
TGF-β 1 antibody according to manufacturer’s instructions
(R&D Systems Inc., Minneapolis, MN, U.S.A.). In short,
100 μ L of the capture antibody was transferred to ELISA plate
and incubated overnight at room temperature. After washing
wells with wash buffer, the plates were blocked by 300 μ L of
PBS containing 5% Tween 20, 5% sucrose and 0.05% NaN3
to each well and incubated at room temperature for 1 hr. Blood
plasma was added 100 μ L per each well. The ELISA plate was
covered with an adhesive strip and incubated 2 hr at room
temperature. Streptavidin HRP (R&D Systems, 1/200 in
appropriate diluent) was added 100 μ L per each well. Then
the plate was covered and incubated for 20 min at room tem-
perature. After subsequent addition of substrate solution and
stop solution (R&D Systems), the optical density of each well
was determined within 30 min at 450 nm.
Statistical analysis
Numerical values are expressed as mean±standard devia-
tion. The Kolmogorov-Smirnov test showed that the TGF-
β 1 values did not fit a standard distribution curve, i.e. the
distribution of the TGF-β 1 levels were positively skewed.
We used nonparametric Mann-Whitney test, Kruskal-Wal-
lis test and correlation analysis with Statistica 7.0 (StatSoft
Inc., Tulsa, OK, U.S.A.). The statistical significance level was
set at P<0.05. 
RESULTS
The mean age of patients with alcohol dependence and
healthy controls were 45.2±9.2 and 48.3±10.1 yr, respec-
tively (Table 1). There were no difference between patients
of alcohol dependence and control subjects in age (P=0.15),
in weight (P=0.13) and in height (P=0.84). As seen in Fig. 1,
mean plasma TGF-β 1 levels in the patients with alcohol depen-
dence (1,653.11±532.45 pg/mL) were higher than in the
control subjects (669.87±366.53 pg/mL) (P=0.000). Alco-
hol induced liver pathology were found with 16 patients after
ultrasonography or computed tomography and consultation.
Fatty liver was diagnosed in 2, alcoholic hepatitis was diag-
nosed in 8. Six turned out to be alcoholic cirrhosis patients.
Comparison TGF-β 1 level between alcohol dependence pati-
ents with or without liver pathology showed no difference
(z=-0.91, P=0.36) (Fig. 2) However, when compared with
control group, TGF-β 1 levels showed significant difference (P=
0.00) in alcohol dependence patients disregarding the pres-
ence or abseuce of liver pathology (P=0.00). Levels of TGF-
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Clinical characteristics
Range
Patients with 
alcohol depen-
dence (n=41)
Normal 
controls
(n=41)
Mean±S.D. Mean±S.D.
Age (yr) 48.3±10.1 45.2±9.2
Height (cm) 167.3±7.0 167.7±7.5
Weight (kg) 59.7±11.7 65.2±11.7
Alcohol use
Age of first use (yr) 21±5.0 15-33 -
Average daily consumption 10.6±4.8 2.1-25.8 -
(standard drinks)
Duration of dependence (yr) 12.1±10.4 1-28 -
Table 1. Characteristics of the normal controls and the patients
with alcohol dependence
Fig. 1. Plasma TGF-β 1 level between alcohol dependence patients
and normal controls.
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Min-Maxβ 1 had no correlation with mean daily alcohol consumption,
age of first use, and duration of dependency (P=0.97, P=0.79,
P=0.77).
DISCUSSION
Our finding verified that TGF-β 1 is increased also in human
alcoholism. Mean plasma TGF-β 1 levels in the patients with
alcohol dependence were higher than in the control subjects.
There had been an increased TGF-β 1 mRNA in the patients
with alcoholic hepatitis and alcoholic cirrhosis. But no dif-
ference had been found between alcohol abuser and normal
controls (16). We found that alcohol dependence without liver
pathology (no proof of fatty liver, hepatitis, cirrhosis with
ultrasonography or computed tomography) had as high
TGF-β 1 as patients with liver pathology (Fig. 2). It may be
possible to consider TGF-β 1 increase as a predictor of alco-
hol induced liver damage.
Chronic alcohol drinking impairs intestinal barrier and
decreases hepatic clearance, resulting in increased endotoxin
levels in the liver (3, 17). These endotoxin bind with lipopoly-
saccharide (LPS)-binding protein which binds CD14 recep-
tor at the Kupffer cell (18). Activated Kupffer cell releases
TGF-β 1 in paracrine pattern that activates hepatic stellate
cell which is a major fibroblastic cell type in liver. In early
stage hepatic stellate cell is highly responsive to TGF-β 1 and
transdifferentiate into myofibroblasts (19, 20). Receptor bind-
ed TGF-β 1 activate Smad family which in turn translocate
into nucleus and regulates target gene expressions (21).
Increased TGF-β 1 induce hepatocyte apoptosis by produc-
ing oxidative stress in rat study (8). This effect is enhanced
by ethanol stimulated CYP2E1 increase, especially in perive-
nous area of liver (22, 23). 
Neuronal migration and neurite outgrowth are mediated
by cell adhesion proteins (CAPs) such as neural cell adhesion
molecule L1, and isoforms of integrin, which are regulated
by TGF-β(24). Radial glia, which is a key element of guid-
ing neuronal migration, mainly expresses TGF ligands and
receptors (25-27) and also expresses cell adhesion proteins (28).
TGF-β 1 promotes CAP transcription and expression in low
concentration, but at much higher concentration it decrease
neuronal migration (12, 24). Thus, increased plasma TGF-β 1
in alcoholism may suppress normal brain function. 
Limitation of our study is that we checked only plasma
TGF-β 1 but did not checle the levels in cerebrospinal fluid.
TGF-β 1 does not cross the intact blood-brain barrier (29).
However in normal condition only choroid plexus epithelial
and meningeal cells express TGF-β 1, but with brain lesion
much induction occurs in other cell types (30). Another lim-
itation of our study is that all of the subjects of our study
were men. So we need a study in female patients to general-
ize our results.
Our result, increased plama TGF-β 1 in alcohol dependence
patients, suggests that alcohol induced liver damage and sup-
pression of normal brain function may be mediated by TGF-
β 1. Alcohol induced liver fibrosis, heptocyte apoptosis, and
neuronal suppression may be mediated by increased TGF-β 1
in alcohol dependent patients. Further study about optimal
suppression of TGF-β 1 that can possibly prevent alcohol in-
duced liver damage and cognitive impairment is needed.
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Fig. 2. Plasma TGF-β 1 levels of alcohol dependence patients with
or without liver pathology and normal controls.
AD, alcohol dependence; LD, liver disese.
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